BridgeBio Pharma (BBIO) Enterprise Value (2017 - 2026)

BridgeBio Pharma has disclosed Enterprise Value across 10 years of filings, most recently posting -$929.7 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$929.7 million, down 75.21% year-over-year; the trailing twelve-month figure through Mar 2026 was -$929.7 million (down 75.21% YoY), and the FY2025 annual result was -$576.9 million, up 14.02% from the prior year.
• Enterprise Value came in at -$929.7 million for Q1 2026 at BridgeBio Pharma, down from -$576.9 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$255.4 million in Q3 2024 to a low of -$929.7 million in Q1 2026.
• The 5-year median for Enterprise Value is -$530.6 million (2025), against an average of -$523.2 million.
• Across the five-year window, Enterprise Value surged 54.13% in 2023 and slumped 75.21% in 2026, its largest moves.
• BridgeBio Pharma's Enterprise Value stood at -$403.3 million in 2022, then retreated by 5.03% to -$423.6 million in 2023, then plunged by 58.38% to -$671.0 million in 2024, then rose by 14.02% to -$576.9 million in 2025, then sank by 61.17% to -$929.7 million in 2026.
• The last three Enterprise Value figures came in at -$929.7 million (Q1 2026), -$576.9 million (Q4 2025), and -$276.0 million (Q3 2025), per Business Quant data.